Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report

Trastuzumab, as a recombinant IgG1 kappa, is a humanized monoclonal antibody against human epidermal growth factor receptor 2. Accordingly, it is widely used in breast cancers at early and advanced stages. Dermatomyositis is a rare adverse event of trastuzumab therapy, which is not well documented y...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghimi, Minoosh, Khodadadi, Kasra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339515/
https://www.ncbi.nlm.nih.gov/pubmed/34413744
http://dx.doi.org/10.1159/000517819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339515/
https://www.ncbi.nlm.nih.gov/pubmed/34413744
http://dx.doi.org/10.1159/000517819

Ejemplares similares